What is VYGR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.15B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VYGR?

P/E (TTM) is n/a and 52-week range is $2.33 to $5.55 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VYGR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VYGR?

The company profile lists revenue (TTM) near $34M, net income (TTM) near $-10.75B, EPS (TTM) near $-1.81 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Voyager Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Lexington, Massachusetts, US, 60.4M shares outstanding, ISIN US92915B1061 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Voyager Therapeutics Inc

$VYGR

Health Care · Biotechnology

IR Run Scenarios

$2.45

+3.38%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Lexington, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2015-11-11. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.

Employees

141

Website

www.voyagertherapeutics.com/

IPO

2015-11-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)